359 related articles for article (PubMed ID: 25218759)
1. The role of NMDA receptors in the pathophysiology and treatment of mood disorders.
Ghasemi M; Phillips C; Trillo L; De Miguel Z; Das D; Salehi A
Neurosci Biobehav Rev; 2014 Nov; 47():336-58. PubMed ID: 25218759
[TBL] [Abstract][Full Text] [Related]
2. Glutamatergic NMDA Receptor as Therapeutic Target for Depression.
Réus GZ; Abelaira HM; Tuon T; Titus SE; Ignácio ZM; Rodrigues AL; Quevedo J
Adv Protein Chem Struct Biol; 2016; 103():169-202. PubMed ID: 26920690
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of action and clinical efficacy of NMDA receptor modulators in mood disorders.
Ghasemi M; Phillips C; Fahimi A; McNerney MW; Salehi A
Neurosci Biobehav Rev; 2017 Sep; 80():555-572. PubMed ID: 28711661
[TBL] [Abstract][Full Text] [Related]
4. NMDA receptor antagonists for depression: Critical considerations.
Serafini G; Gonda X; Rihmer Z; Pompili M; Girardi P; Nasrallah HA; Amore M
Ann Clin Psychiatry; 2015 Aug; 27(3):213-20. PubMed ID: 26247220
[TBL] [Abstract][Full Text] [Related]
5. Emerging role of glutamate in the pathophysiology of major depressive disorder.
Hashimoto K
Brain Res Rev; 2009 Oct; 61(2):105-23. PubMed ID: 19481572
[TBL] [Abstract][Full Text] [Related]
6. Ketamine as an alternative treatment for treatment-resistant depression.
Dowben JS; Grant JS; Keltner NL
Perspect Psychiatr Care; 2013 Jan; 49(1):2-4. PubMed ID: 23293991
[No Abstract] [Full Text] [Related]
7. The role of NMDA receptor in neurobiology and treatment of major depressive disorder: Evidence from translational research.
Amidfar M; Woelfer M; Réus GZ; Quevedo J; Walter M; Kim YK
Prog Neuropsychopharmacol Biol Psychiatry; 2019 Aug; 94():109668. PubMed ID: 31207274
[TBL] [Abstract][Full Text] [Related]
8. Molecular and cellular dissection of NMDA receptor subtypes as antidepressant targets.
Lang E; Mallien AS; Vasilescu AN; Hefter D; Luoni A; Riva MA; Borgwardt S; Sprengel R; Lang UE; Gass P; Inta D
Neurosci Biobehav Rev; 2018 Jan; 84():352-358. PubMed ID: 28843752
[TBL] [Abstract][Full Text] [Related]
9. The "blue" side of glutamatergic neurotransmission: NMDA receptor antagonists as possible novel therapeutics for major depression.
Szakacs R; Janka Z; Kalman J
Neuropsychopharmacol Hung; 2012 Mar; 14(1):29-40. PubMed ID: 22427468
[TBL] [Abstract][Full Text] [Related]
10. Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
Kishimoto T; Chawla JM; Hagi K; Zarate CA; Kane JM; Bauer M; Correll CU
Psychol Med; 2016 May; 46(7):1459-72. PubMed ID: 26867988
[TBL] [Abstract][Full Text] [Related]
11. NMDA antagonists under investigation for the treatment of major depressive disorder.
Pochwat B; Pałucha-Poniewiera A; Szewczyk B; Pilc A; Nowak G
Expert Opin Investig Drugs; 2014 Sep; 23(9):1181-92. PubMed ID: 24818801
[TBL] [Abstract][Full Text] [Related]
12. N-methyl-D-aspartate glutamate receptor antagonists and the promise of rapid-acting antidepressants.
Krystal JH
Arch Gen Psychiatry; 2010 Nov; 67(11):1110-1. PubMed ID: 21041611
[No Abstract] [Full Text] [Related]
13. The chemical biology of clinically tolerated NMDA receptor antagonists.
Chen HS; Lipton SA
J Neurochem; 2006 Jun; 97(6):1611-26. PubMed ID: 16805772
[TBL] [Abstract][Full Text] [Related]
14. The NMDA receptor complex as a therapeutic target in epilepsy: a review.
Ghasemi M; Schachter SC
Epilepsy Behav; 2011 Dec; 22(4):617-40. PubMed ID: 22056342
[TBL] [Abstract][Full Text] [Related]
15. The role of glutamate on the action of antidepressants.
Hashimoto K
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Aug; 35(7):1558-68. PubMed ID: 20600468
[TBL] [Abstract][Full Text] [Related]
16. Changes in cortical N-methyl-D-aspartate receptors and post-synaptic density protein 95 in schizophrenia, mood disorders and suicide.
Dean B; Gibbons AS; Boer S; Uezato A; Meador-Woodruff J; Scarr E; McCullumsmith RE
Aust N Z J Psychiatry; 2016 Mar; 50(3):275-83. PubMed ID: 26013316
[TBL] [Abstract][Full Text] [Related]
17. Glutamatergic modulators: the future of treating mood disorders?
Zarate C; Machado-Vieira R; Henter I; Ibrahim L; Diazgranados N; Salvadore G
Harv Rev Psychiatry; 2010; 18(5):293-303. PubMed ID: 20825266
[TBL] [Abstract][Full Text] [Related]
18. Changes in Muscarinic M2 Receptor Levels in the Cortex of Subjects with Bipolar Disorder and Major Depressive Disorder and in Rats after Treatment with Mood Stabilisers and Antidepressants.
Gibbons AS; Jeon WJ; Scarr E; Dean B
Int J Neuropsychopharmacol; 2016 Apr; 19(4):. PubMed ID: 26475745
[TBL] [Abstract][Full Text] [Related]
19. Prescribing patterns of antidepressants, antipsychotics and mood stabilizers in bipolar patients misdiagnosed with major depressive disorder in China.
Xiang YT; Hu C; Wang G; Zheng QW; Fang YR; Ungvari GS; Kilbourne AM; Lai KY; Si TM; Chen DF; Lu Z; Yang HC; Hu J; Chen ZY; Huang Y; Sun J; Wang XP; Li HC; Zhang JB; Chiu HF
Hum Psychopharmacol; 2012 Nov; 27(6):626-31. PubMed ID: 23027671
[TBL] [Abstract][Full Text] [Related]
20. Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status.
Henter ID; Park LT; Zarate CA
CNS Drugs; 2021 May; 35(5):527-543. PubMed ID: 33904154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
